The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone

Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan-Rong, Liu, Chi-Hung, Sun, Wei-Chiao, Fan, Pei-Yi, Liu, Feng-Hsuan, Chen, Tien-Hsing, Wu, Victor Chien-Chia, Lin, Chihung, Hsiao, Ching-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472235/
https://www.ncbi.nlm.nih.gov/pubmed/34575605
http://dx.doi.org/10.3390/jpm11090828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472235/
https://www.ncbi.nlm.nih.gov/pubmed/34575605
http://dx.doi.org/10.3390/jpm11090828

Ejemplares similares